source
- Biohaven could get up to $795M in epilepsy alliance with SK BioAt the center of Biohaven’s agreement with SK Biopharmaceutical is the ion channel platform and the lead epilepsy candidate opakalim, for which Phase 2/3 data are expected later this year.BioSpace · 2h ago↗ source
- Turkish antitrust regulator launches probe into Teva for alleged patent manipulation and false claims about rivalsTurkish competition authorities have opened an investigation into Teva Pharmaceutical, the world’s largest generic drugmaker, accusing the company of manipulating the patent system and making misle…